The Coagulation Factor XII pipeline drugs market research report outlays comprehensive information on the Coagulation Factor XII targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Coagulation Factor XII pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Cardiovascular, Immunology, Central Nervous System, and Infectious Disease which include the indications Thrombosis, Thromboembolic Disease, Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), Inflammation, Intracerebral Hemorrhage, and Infectious Disease. It also reviews key players involved in Coagulation Factor XII targeted therapeutics development with respective active and dormant or discontinued products.
The Coagulation Factor XII pipeline targets constitutes close to ten molecules. Out of which, approximately nine molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical, and Discovery stages are 1, 1, 1, 5, and 1 respectively. Similarly, the universities portfolio in Discovery comprises 1 molecule.
Coagulation Factor XII overview
Coagulation factor XII (F12) is a protein involved in the blood clotting process, specifically in the intrinsic pathway of coagulation. It is one of the many clotting factors that work together to stop bleeding and maintain hemostasis, which is the body’s ability to maintain a stable state of internal blood balance. Factor XII is produced in the liver and circulates in the bloodstream in an inactive form.
For a complete picture of Coagulation Factor XII’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
